SCHEMBL3675102

SCHEMBL3675102

COc1ccc(C2CCC(C(C)(C)C)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.49
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
KDM1A O60341 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ADRA1A P35348 1/20 0.42
HTR2C P28335 1/20 0.41
THRB P10828 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12227839 0.89 DRD2 (0.49) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL1515026 0.86 DRD2 (0.59) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL12603883 0.84 DRD2 (0.47) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL12603884 0.84 DRD2 (0.47) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL22209909 0.83 KDM1A (0.48) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL9336546 0.81 DRD2 (0.45) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL803244 0.79 ESR2 (0.59) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL12360680 0.78 DRD2 (0.43) DRD2ALDH1A1SMN1; SMN2MAPTCYP2C9
SCHEMBL1515040 0.78 DRD2 (0.56) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A
SCHEMBL2095118 0.78 ALDH1A1 (0.56) DRD2ALDH1A1SMN1; SMN2MAPTKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781599-B2 economical; nontoxic; high yield; industrial scale; Grignard reaction; iron catalyst (FeCl3) and a diamine (ethylenediamine); cross-coupling of alkyl halide and aromatic organometallic; primary or secondary alkyl substituents; phenylcycloheptane from bromocycloheptane and phenyl magnesium bromide JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2010-08-24 US disclosed
US-20070123734-A1 Process for production of aromatic compounds JAPAN SCIENCE AND TECHNOLOGY AGENCY 2007-05-31 US disclosed
EP-1724248-A1 PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS Japan Science and Technology Agency (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123734-A1 Process for production of aromatic compounds C9, C5, C1S DRD2 700/4885ALDH1A1 2363/4885SMN1; SMN2 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.